Background & Aims Proactive therapeutic drug monitoring (TDM) has been proposed to
improve outcomes in patients with inflammatory bowel disease (IBD) treated with tumor …

Background: The contemporary management of ambulatory ulcerative colitis (UC) continues
to be challenging with∼ 20% of children needing a colectomy within childhood years. We …

The incidence of inflammatory bowel disease (IBD) has increased steadily worldwide, both
in adult and in children; approximately 25% of IBD patients are diagnosed before the age of …

The rate of pediatric inflammatory bowel disease (IBD) has been increasing over the last
decade and this increase has occurred most rapidly in the youngest children diagnosed< 6 …

Infliximab (IFX) is administered intravenously using weight-based dosing (5 mg/kg) in
inflammatory bowel disease (IBD) patients. Our hypothesis is that especially young children …

Background Scarce data are available on the use of vedolizumab in children with
inflammatory bowel disease (IBD). We aimed to evaluate the safety, effectiveness, and …

Background Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with
inflammatory bowel disease [IBD], but the data in paediatrics are limited. We describe the …

Background Insight into the pathogenesis of very early onset-inflammatory bowel disease
(VEO-IBD) has expanded through the identification of causative monogenic defects detected …

Introduction The optimal trial design for assessing novel therapies in paediatric IBD (PIBD) is
a subject of intense ongoing global discussions and debate among the different …

Introduction: Crohn's disease and Ulcerative Colitis are forms of inflammatory bowel disease
(IBD), chronic diseases treated with medical and surgical therapy. Patients with IBD are …